Active, not recruitingPhase 3NCT05070858
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Pozelimab + Cemdisiran(drug)
- Enrollment
- 288 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- HonorHealth Neurology 2018, Scottsdale, Arizona, United States
- University of California Irvine, Irvine, California, United States
- University of Southern California, Los Angeles, California, United States
- Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States
- SFM Clinical Research, LLC, Boca Raton, Florida, United States
- Diverse Clinical Research, Miami, Florida, United States
- Aqualane Clinical Research, Naples, Florida, United States
- Neurological Services of Orlando, Orlando, Florida, United States
- Medsol Clinical Research Center Inc, Port Charlotte, Florida, United States
- University of South Florida Morsani Center for Advanced Healthcare, Tampa, Florida, United States
- NorthShore University Health System, Glenview, Illinois, United States
- St. Elizabeth's Hospital, O'Fallon, Illinois, United States
- Northwest Neurology Ltd. - Clinedge - PPDS, Rolling Meadows, Illinois, United States
- Wayne State University School of Medicine, Detroit, Michigan, United States
- Dayton Center for Neurological Disorders, Centerville, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05070858 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.